Replies to post #133614 on Biotech Values

[poorgradstudent]

Though I don't think the deal was as good as my expectations, it's better than my initial gut feeling after having read through and thought about the 8-K disclosures a little more.

I know what you're saying, but I think it's important to distinguish the types of deals that MNTA will enter into versus those of companies like PCYC. One has a proprietary drug, whereas in most instances MNTA isn't offering a drug but rather analytical services.

The 8K even refers to this by noting that MNTA stands to gain if they can lessen the regulatory burden for approval of the molecules under consideration. As it stands, I think it's a fine deal for the type of company that MNTA is.